Stephen Baylin elected to the National Academy of Sciences, USA

By |2017-07-22T09:59:46+01:00July 17th, 2017|News|

We are proud to announce that Prof. Stephen B. Baylin, Officer at the Cancer Epigenetics Society and Editor of Cancer Epigenetics, was elected to the National Academy of Sciences, USA. This distinction is in recognition of his work in basic and applied research in the fields of epigenetics and cancer epigenetics. Prof. Baylin has [...]

Arid1a: a fertile target in the parched anticancer drug landscape

By |2017-05-19T11:28:44+01:00November 17th, 2016|News|

Recent work from several labs have shown ARID1A, the helicase/ATPase-containing SWI/SNF chromatin-remodeling factor, to be mutated in several cancers, most notably in ovarian cancer (some 50% of ovarian clear-cell carcinoma). Other cancers in which ARID1A was reported to be mutated include Sézary syndrome (a leukemic form of cutaneous T cell lymphoma; ~26%), pancreatic cancer (~25%), breast [...]

Update on the Cancer Epigenetics Clinical Trials Database

By |2017-05-19T11:28:44+01:00August 17th, 2016|News|

The Cancer Epigenetics Society has continued expanding its cancer epigenetic drug clinical trial repository which now covers 500+ clinical trials. These include most if not all reported completed, ongoing, and recruiting cancer clinical trials on DNA methyltransferases (DNMTi), histone deacetylases (HDACi), histone methyltransferases (HMTi), and histone demethylases (KDMi). All databases are currently freely accessible to [...]

Empowering Cancer patients

By |2017-05-19T11:28:44+01:00June 28th, 2016|News|

As a member of the US National Coalition for Cancer Survivorship (NCCS), the Cancer Epigenetics Society asks our members in the States with interest in cancer treatment and survival to help support cancer advocacy in the US. One such initiative is currently undergoing under the umbrella of NCCS to provide a boost  to the bipartisan [...]

After cancer prevention, aspirin steps up to the plate of cancer treatment?!

By |2018-01-28T13:49:50+01:00June 3rd, 2016|News|

We recently reported that frequent low-dose intake of aspirin reduces the risk of developing colorectal and bile duct cancers (read it here). Now a new study from Norway shows that taking aspirin after cancer diagnosis improves survival of people diagnosed with colorectal cancer. In a collaboration between the Cancer Registry of Norway, the Norwegian Institute [...]

Radon: radioactivity at home, the silent killer

By |2016-05-20T13:26:35+01:00May 20th, 2016|News|

Recent research from scientists in the US, Canada, and Europe show that residential radon can increase the risk of hematological cancers, particularly of follicular lymphoma and diffuse large B-cell lymphoma. The study analyzed data from 140,652 people in 20 US states and over nearly two decades that were grouped into low (< 74 Becquerel/m³), medium [...]

Find us on YouTube!

By |2017-05-19T11:28:44+01:00May 18th, 2016|News|

We proudly announce that CES has now its own YouTube channel! We have released our first video which gives a quick overview of the history of DNA chemical changes that accompany many different cellular processes, including those involved in cancer. These changes, the most common of which being DNA methylation, represents one of the most [...]

One aspirin a day keeps the doctor at bay?

By |2017-05-19T11:28:44+01:00May 10th, 2016|News|

While it is now well established that low-dose, daily or frequent use of aspirin can considerably reduce the risk of cardiovascular disease and colorectal cancers, new findings from the Mayo Clinic at Rochester (MN, USA) show that aspirin can also reduce the risk of cholangiocarcinoma or bile duct cancers. In this study that included [...]

Cooling the scalp to preserve hair during chemo approved in the US:

By |2018-01-28T15:55:28+01:00May 9th, 2016|News|

A method that has been used for some 40 years in Europe to reduce hair loss during chemotherapy, which consists of cooling the scalp with a cold cap, has finally been approved by the United States Food and Drug Administration (FDA) for use by cancer patients in the US. The method was met for [...]

Go to Top